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Background: Pancreatic cancer (PC) is an aggressive disease with an urgent need for biomarkers. Hallmarks of PC
include increased collagen deposition (desmoplasia) and increased matrix metalloproteinase (MMP) activity. The aim
of this study was to investigate whether protein fingerprints of specific MMP-generated collagen fragments
differentiate PC patients from healthy controls when measured in serum.
Methods: The levels of biomarkers reflecting MMP-mediated degradation of type I (C1M), type III (C3M) and type IV
(C4M, C4M12a1) collagen were assessed in serum samples from PC patients (n = 15) and healthy controls (n = 33)
using well-characterized and validated competitive ELISAs.
Results: The MMP-generated collagen fragments were significantly elevated in serum from PC patients as
compared to controls. The diagnostic power of C1M, C3M, C4M and C4M12 were ≥83% (p < 0.001) and when
combining all biomarkers 99% (p < 0.0001).
Conclusions: A panel of serum biomarkers reflecting altered MMP-mediated collagen turnover is able to
differentiate PC patients from healthy controls. These markers may increase the understanding of mode of action of
the disease and, if validated in larger clinical studies, provide an improved and additional tool in the PC setting.
Keywords: Extracellular matrix remodeling, Collagen turnover, Biomarker, Serological detection,
Matrix metalloprotease, Pancreatic cancerBackground
Pancreatic cancer (PC) is an aggressive disease with a
poor prognosis at time of diagnosis. It is estimated that
roughly 80,000 people will die of the disease in 2013 in
the EU and US [1,2]. At present, surgery is the only po-
tentially curative therapy for PC as most tumors are un-
responsive to basically all therapies [3]. Due to a lack of
specific clinical symptoms, most patients have unresect-
able primary tumors and/or metastatic spread at the
time of diagnosis, resulting in incurative disease. These
facts make PC one of the top five most lethal types of
cancer with approximately 70% of patients dying within* Correspondence: nwi@nordicbioscience.com
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reproduction in any medium, provided the orthe first year of diagnosis and with a five year survival
rate at 5%. Consequently, there is an urgent medical
need for biomarkers that can help making the diagnosis
and prognosis of PC as well as assisting in monitoring
recurrence of the disease and the response to treatment.
Among the different types of PC, pancreatic ductal
adenocarcinoma (PDAC) accounts for almost 90% of cases
[4]. In PDAC the stroma comprises approximately 80% of
the tumor mass. The tumor stroma is characterized by the
presence of cells such as fibroblast, endothelial cells and
immune cells as well as by a dense and stiff extracellular
matrix (ECM) referred to as desmoplasia. Desmoplasia is
similar to fibrotic tissue and includes proteins such as colla-
gens, fibronectin, proteoglycans and hyaluronic acid.
In many types of cancer, due to altered ECM remodel-
ing from the desmoplastic reaction and an increased
matrix metalloproteinase (MMP) activity [5], the tissuetral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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position and quality of the ECM [6]. Especially, the
interstitial fibrillar type I and III collagen [7], as well as
the basement membrane protein type IV collagen [8,9]
play important roles in tissue homeostasis alterations as-
sociated with PC. As a consequence of the altered ECM
remodeling, ECM degradation fragments that contain
specific neopeitopes, referred to as protein fingerprints,
may be released to the circulation where they can be
assessed and serve as surrogate markers of an altered
ECM remodeling [10].
The aim of this study was to investigate whether pro-
tein fingerprints of specific MMP-generated collagen
protein fragments may differentiate PC patients from
healthy controls when measured in serum.Methods
Patient serum samples
Patient serum samples were obtained from the commercial
vendor Asterand (Detroit, MI). Asterand confirms that the
following activities have been completed by their collabora-
tors (as necessary): institutional and independent review
board approval, privacy officer authorization, government
licenses, or industry accreditations. All their informed con-
sent templates were subject to review and approval by ap-
propriate regulatory and ethics authorities. According to
Danish law, it is not required to get ethical approval when
measuring biochemical markers in previously collected
samples; hence, there was no additional ethical approval for
this particular study. The serum was collected from 15 pa-
tients with pancreatic ductal adenocarcinomas (PDAC)
prior to resection, and 33 age- and sex-matched controls
with no symptomatic or chronic disease (Table 1). Samples
were collected, processed and stored in a similar fashion
until analyzed, and all analyses were performed blindly. The
study was conducted according to the Principal of Good
Clinical Practice and according to the Declaration of
Helsinki.ELISA measurements and procedure
Using well-characterized and validated competitive ELI-
SAs, levels of MMP-2/-9/-13 degraded collagen type I
(C1M) [11], MMP-9 degraded collagen type III (C3M)
[12], MMP-9 degraded collagen type IV (C4M) [13] and
MMP-12 degraded collagen type IV (C4M12a1) [14]
were assessed in serum samples. The targets wereTable 1 Patient characteristics
Group No. of patients Stage
I II III
PDAC 15 3 8 1
Healthy controls 33identified from in vitro and ex vivo studies and by use of
mass spectrometry (see references for details).
In brief, the individual serum biomarkers were
assessed using a 96-well streptavidin-plate coated with a
biotinylated specific synthetic peptide dissolved in an op-
timized assay buffer that was incubated for 30 minutes
at 20°C. The plate was washed five times in washing-
buffer (20 mM Tris, 50 mM NaCl, pH 7.2) prior to
adding 20 μL of peptide calibrator or sample to the ap-
propriate wells. This was followed by the addition of
100 μL of a HRP-conjugated target-specific monoclonal
antibody. The plate was incubated for 1 hour at 20°C or
overnight at 4°C, depending on the assay, and was then
washed five times in washing-buffer. Finally 100 μL tet-
ramethylbenzinidine (Kem-En-Tec cat.438OH) was
added and the plate incubated for 15 minutes at 20°C in
darkness before adding 100 μL stopping solution (1%
H2SO4). The OD of each well was measured at 450 nm
with 650 nm as reference.
Statistical analysis
Biomarker levels from controls and patients were com-
pared using an unpaired t-test on Log10 transformed
data and are presented as Tukey box plots. Tumor stage
was compared to controls by ANOVA. The area under
the receiver operating characteristics (AUROC) was cal-
culated for each biomarker and for all the biomarkers
combined. Statistical analyses were performed using
MedCalc Statistical Software v.12 (MedCalc Software,
Ostend, Belgium). Results were considered statistically
significant if p < 0.05.
Results
MMP-mediated degradation of collagen
Levels of MMP-generated fragments of collagen type I,
III and IV were significantly elevated in serum from PC
patients as compared to controls (Figure 1). In detail,
the level of MMP-2/-9/-13 degraded collagen type I
(C1M) was 4-fold higher in PC patients as compared to
controls and the levels of MMP-9 degraded collagen
type III (C3M), MMP-9 degraded collagen type IV
(C4M) and MMP-12 degraded collagen type IV
(C4M12a1) were 2-fold higher in PC patients as com-
pared to controls. Together, these findings indicate that
altered collagen-remodeling is ongoing in PC.
As the tumor stage is an important clinical tool in PC,
the levels of MMP-generated fragments of type I (C1M),Gender, %
females
Age, years
IV Unknown Mean ± SD (range)
- 3 40% 65 ± 8 (48 – 84)
52% 61 ± 11 (43 – 78)
Figure 1 Levels of MMP-generated fragments of type I, III and IV collagen are significantly elevated in serum from PC patients as
compared to controls. Biomarkers of MMP-2/-9/-13 mediated degradation of collagen type I (C1M), MMP-9 mediated collagen type III (C3M)
and MMP-9 mediated (C4M) and MMP-12 mediated (C4M12a1) degradation of collagen type IV in serum from patients with pancreatic ductal
adenocarcinomas (PDAC) (n = 15) and healthy controls (n = 33). Groups were compared using an unpaired t-test on Log transformed data. Results
are presented as Tukey box plots, boundaries of each box indicate 25th and 75th percentiles, the line within the box marks the median and
whiskers indicate maximum and minimum. Significance levels: **p < 0.01, ****p < 0.0001.
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gen from PC patients as divided by tumor stage is illus-
trated in Figure 2. In detail, both patients in stage 1 and
stage 2 had significantly elevated levels of C1M and
C4M12a1 as compared to controls. The same was true
for C3M and C4M, however only significant in stage 2
of the disease (clearly a trend was observed for elevated
levels of these markers in stage 1 as well). Finally, the
single patient in stage 3 was, for all markers tested ex-
cept C3M, completely separated from the control group.
Diagnostic power of biomarkers to discriminate between
healthy and PC cases
The area under the receiver operating characteristic
(AUROC) was calculated as a measure of the diagnostic
power of the biomarkers individually as well as com-
bined in healthy controls vs. PC (Table 2). The diagnos-
tic power of C1M, C3M, C4M and C4M12a1 was highly
significant with an AUROC ≥83% (p < 0.001). WhenFigure 2 Levels of MMP-generated fragments of type I (C1M), type III
as divided by tumor stage. Biomarkers of MMP-2/-9/-13 mediated degrad
(C3M) and MMP-9 mediated (C4M) and MMP-12 mediated (C4M12a1) degr
patients had unreported stage) with pancreatic ductal adenocarcinomas (P
by ANOVA on Log transformed data. Significance levels: *p < 0.05, **p < 0.0combining all biomarkers, a diagnostic power of 99%
(p < 0.0001) was achieved, indicating that the combin-
ation of all biomarkers leads to a complete discrimin-
ation between healthy controls and PC patients.
Discussion
In this study we tested a panel of collagen degradation
biomarkers in patients with pancreatic ductal adenocar-
cinomas (PDAC). Interestingly, significant differences in
the biomarker levels were seen between healthy and dis-
eased individuals. To our knowledge, this is the first
study investigating the MMP-mediated turnover profile
of several collagens in serum from PC patients.
The elevated levels of the biomarkers indicate that the
normal homeostatic balance is changed in PC tissue.
This may be caused both by increased local deposition
and degradation of the ECM as desmoplasia (cancer as-
sociated fibrosis) which is a hallmark of PDAC [7],
shares many similarities with general fibrosis where(C3M) and type IV (C4M and C4M12a1) collagen from PC patients
ation of type I collagen (C1M), MMP-9 mediated type III collagen
adation of type IV collagen in serum from the patients (three of the
DAC) and healthy controls. Stage 1 and 2 were compared to controls
1, ***p < 0.01, ****p < 0.0001.
Table 2 Area under the receiver operating characteristic (AUROC) in discriminating between healthy controls and PC
patients
Biomarker AUROC Std. Error 95% confidence interval P value
C1M 0.83 0.067 0.701 to 0.963 <0.001
C3M 0.88 0.048 0.792 to 0.978 <0.0001
C4M 0.94 0.039 0.860 to 1.02 <0.0001
C4M12a1 0.89 0.046 0.805 to 0.985 <0.0001
All biomarkers combined 0.99 0.005 0.918 to 1.00 <0.0001
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IV [13] can be found in serum where it is linked to the
ECM remodeling (production and degradation). In line
with this desmoplasia is a dynamic process that contrib-
utes directly to malignancy through altered integrin sig-
naling [15].
During PDAC progression the normal basement mem-
brane architecture is lost and cancer cells have been
found to be in direct contact with the interstitial matrix,
i.e. type I and type III collagens [7]. Basement membrane
protein alterations, such as collagen type IV degradation,
have also been found to contribute to malignancy by en-
hancing the invasive behavior of pancreatic cancer cells
[8]. Similar to our findings, collagen type IV has previ-
ously been found in serum of PC patients and linked (in-
directly) to tissue remodeling [16]. Interestingly, in that
study increased levels of circulating type IV collagen
could be observed preoperatively, and postoperatively
levels either increased or decreased with high levels cor-
responding to poor prognosis and short survival time.
All together this indicates that MMP-driven remodeling
of collagen type IV may be linked to severity and pro-
gression of the disease.
Elevated levels of circulating fragments of collagen
type I, III and IV have been associated with different
cancer types, including head and neck cancer [17],
breast cancer [18,19], liver cancer [20], colorectal liver
metastases [21] and for the hepatic failure following liver
resection for hepatocellular carcinoma [22]. This indi-
cates that collagen degradation and release of fragments
to the circulation is an ongoing event in many types of
cancer, and that collagen degradation markers may be
applicable to disease monitoring in several cancer types.
Novel information may be obtained from the neo-
epitope based nature of the biomarkers applied in the
current study. The neo-epitope technology is based on
the concept that tumor associated proteases (MMPs)
and tumor-tissue signature proteins (high levels of colla-
gens) result in release of unique protein degradation
fragments to the circulation. These protein fragments
contain specific neoepitopes that may be more disease
specific than measuring total protein and/or unspecific
protein degradation fragments and may be indicative of
a dynamic alteration in the tissue and thus containimportant and novel information on mode of action of
the disease. In the tumor microenvironment different
proteases form complex proteolytic networks [23] and it
is likely that different collagens and different proteases
may be associated more or less with individual types of
cancer.
The results presented here indicate that multiple
MMPs are involved in the altered ECM-remodeling as-
sociated with PC. The mechanisms behind the degrad-
ation of the highly complex mixture of ECM proteins
are still not fully understood. Different MMPs display di-
verse and sometimes opposite effects depending on tis-
sue localization, cellular source, stage and cancer
subtype [24,25]. MMPs are also very important in main-
taining a healthy tissue homeostasis. This may also ex-
plain why many anti-MMP treatments tested so far have
failed, i.e. harmful inhibition of the healthy MMP activity
and unwanted inhibition of the anti-tumor effect of an
increased MMP activity [26]. Furthermore, in a complex
way degradation of ECM proteins such as collagen type
IV may have both pro- and anti-tumorigenic effects. For
instance, antibody-targeting denatured type IV collagen
has been found to suppress angiogenesis and tumor
growth in vivo [27,28], whereas the type IV collagen-
derived protein fragments arrestin, canstatin and tumsta-
tin are well described inhibitors of tumor angiogenesis
[29]. In order to effectively target MMPs in cancer, a
better understanding of both their primary and second-
ary pro- and anti-tumorigenic effects is required and it
is well recognized that MMP inhibitor studies should
include biomarkers that reflect activation or inhibition
of specific MMPs in vivo [30]. We speculate that the
neo-epitope based biomarkers could be optimal for
monitoring the ability of either broad-spectrum or se-
lective MMP inhibitors to exhibit anticancer effects and
potentially monitor benefits and/or harms of anti-MMP
treatment. Other MMP-specific neo-epitope based bio-
markers may be developed that could contribute to this
complex issue.
As the collagen degradation biomarkers were elevated
in all stages of the disease, this indicates that the
markers may be applied in the early onset of the disease.
Furthermore, due to the intrinsic dynamic nature of the
markers they may have the potential to identify a sub-
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invasion that may be fast progressing. The importance
of identifying fast progressing patients as early as pos-
sible is emphasized by the increasing evidence support-
ing the idea that attenuating the desmoplastic reaction
and tissue remodeling in general may help limit the pro-
gression of pancreatic cancer. In line with this, findings
show that in patients with small tumors of ≤10-20 mm
in size, and no lymph node or metastatic spread, surgical
resection increased the 5-year survival rates to 30-75%
[31], and retrospective computed tomography (CT)
scans of patients >6 months prior to clinical detection of
the disease showed that PC was, when present, found to
be fully resectable [32]. Furthermore, as a dense stroma
in PDAC has been linked to the formation of a barrier
for chemotherapy exerting its effects, the biomarkers
may potentially be able to separate chemotherapy re-
sponders from non-responders [7,33].
The biomarkers provided excellent diagnostic informa-
tion, especially when combined (Table 2). To fully analyze
the diagnostic applicability of the collagen degradation
markers used here, other types of cancer and diseases such
as pancreatitis should be included in the study. Other limi-
tations include a small sample size, lack of patient informa-
tion and the cross-sectional nature of the study. To date,
no diagnostic examination has proven clinically practical
for PC [34] and consequently there is a need to search for
easily accessible, highly sensitive and specific diagnostic bio-
markers. Blood based biomarkers that may serve as surro-
gates for tumor alterations and hereby avoid invasive
diagnostic techniques are always preferred. The gold stand-
ard serum biomarker related to PC is CA19-9. Major limi-
tations of this biomarker exist however, as only 65% of
patients with resectable PC have elevated levels of CA19-9
[34] and false negative results occur in the Lewis negative
blood type population [35]. Therefore, the American
Society of Clinical Oncology also reports that CA 19–9 is
inadequate for reliable PC diagnosis [36]. Many other
markers have been extensively discussed and tested as sero-
logical markers of PC, however, none have demonstrated
optimal sensitivity and diagnostic value for clinical utility
[34,37]. A panel of markers reflecting different patho-
physiological processes involved in different pancreatic dis-
eases will almost certainly be required for diagnosis, prog-
nosis and assessment of the efficacy of interventions. The
collagen turnover biomarkers may potentially combine with
other tools (such as a recently described 25 protein plat-
form based on the role of the immune system in PDAC
[38]) and add additional information that may improve PC
outcome.
Conclusion
PC is a field with an urgent need for biomarkers that can
aid in the diagnosis of PC and contribute to prediction oftumor burden as well as the early identification of potential
recurrence of the disease or lack of response to a given
intervention. A panel of highly specific (neo-epitope based)
serum biomarkers reflecting altered MMP-mediated colla-
gen turnover differentiate PC patients from healthy con-
trols. These markers may increase the understanding of
mode of action of the disease and, if validated in larger clin-
ical studies, provide an improved and additional tool in the
PC setting.
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